Skip to main content
main-content

The independent medical news service

Lymphoma

10-12-2018 | Lymphoma | News | Article

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

05-12-2018 | Lymphoma | News | Article

Editor's pick

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1804980
ASH 2018; San Diego, California, USA; 1–4 December

20-11-2018 | Oncology | News | Article

approvalsWatch

First-line peripheral T-cell lymphoma, AML drug use announced

Read more on these US FDA and UK NICE approvals here

19-10-2018 | Oncology | News | Article

Post-induction PET predicts outcome in follicular lymphoma

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30618-1

17-10-2018 | Oncology | News | Article

Editor's pick

Duvelisib offers treatment alternative for patients with CLL/SLL

The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.

Source:

Blood 2018; doi:10.1182/blood-2018-05-850461

28-09-2018 | Oncology | News | Article

In other news: Hematologic cancer focus

This month we round-up four hematologic cancer trials, two looking at treatment options for older and younger patients with Hodgkin lymphoma, and two evaluating treatments for smoldering and relapsed or refractory multiple myeloma. Read on to find out more.

20-09-2018 | Lymphoma | News | Article

Hormonal biomarker shows ovarian toxicity of Hodgkin lymphoma treatment

Phase III trial data have highlighted the value of antimüllerian hormone as a biomarker of ovarian toxicity associated with different chemotherapy regimens for advanced Hodgkin lymphoma.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30500-X

07-09-2018 | Lymphoma | News | Article

Circulating tumor DNA predicts DLBCL outcomes

Pretreatment levels of circulating tumor DNA, as well as changes during therapy, are independently prognostic of outcomes in patients with diffuse large B-cell lymphoma and can add to established risk factors, findings indicate.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.5246

06-09-2018 | Lymphoma | News | Article

Lenalidomide plus rituximab comparable to follicular lymphoma standard of care

Treatment-naïve follicular lymphoma patients have similar outcomes regardless of whether they receive lenalidomide or chemotherapy in combination with rituximab, suggest phase III trial findings published in The New England Journal of Medicine.

Source:

N Engl J Med 2018; 379: 934–947

22-08-2018 | Lymphoma | News | Article

Mogamulizumab improves cutaneous T-cell lymphoma outcomes

MAVORIC trial results support the use of the C-C chemokine receptor 4-targeted antibody mogamulizumab over the standard of care vorinostat in previously treated patients with mycosis fungoides or Sézary syndrome.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30379-6
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30449-2

13-08-2018 | Oncology | News | Article

Ibrutinib monotherapy promising for untreated Waldenström macroglobulinemia

Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6426
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.3273

13-08-2018 | Oncology | News | Article

approvalsWatch

Mogamulizumab-kpkc approved for rare NHL subtypes

Read more on this US FDA decision here

03-08-2018 | Oncology | News | Article

News in brief

‘Reassuring’ childbirth rate reported for Hodgkin lymphoma survivors

The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.

27-07-2018 | Oncology | News | Article

In other news: Focus on clinical trial endpoints

This month’s round-up covers three studies evaluating clinical trial endpoints, two focusing on endpoints for programmed cell death protein 1 inhibitor trials and one assessing the surrogacy of progression-free survival in the first-line diffuse large B-cell lymphoma setting. Read on for more details.

16-07-2018 | Oncology | Main feed | News

approvalsWatch

EMA recommends two CAR T-cell therapies for approval

These decisions are reported here

04-07-2018 | Oncology | News | Article

approvalsWatch

FDA expands indications for venetoclax, bevacizumab

More information about these approvals is a click away

18-06-2018 | Lymphoma | Main feed | News

approvalsWatch

Double pembrolizumab approval for advanced cervical cancer, PMBCL

Read more on these US FDA decisions here

03-06-2018 | Lymphoma | News | Article

ASCO 2018 in brief

Ibrutinib, rituximab duo boosts Waldenström macroglobulinemia outcomes

Treatment with the combination of ibrutinib and rituximab results in better outcomes for patients with newly diagnosed or recurrent Waldenström macroglobulinemia than rituximab alone, phase III trial findings indicate.

21-05-2018 | Lymphoma | News | Article

First-line rituximab plus GemOx promising in older patients with DLBCL

The combination of rituximab, gemcitabine, and oxaliplatin has potential for the treatment of older patients with a new diagnosis of diffuse large B-cell lymphoma, suggests a Chinese phase II trial.

Source:

Lancet Haematol 2018; Advance online publication

15-05-2018 | Oncology | News | Article

approvalsWatch

Tisagenlecleucel approved for relapsed, refractory DLBCL

Read more on this CAR T-cell therapy announcement here

image credits